CRISPR Medicine

Sumitomo Pharma

Main (gene editing) focus: Undisclosed

Company stage: Commercial

Diseases: Undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (OTC:DNPUF)

Location: Osaka, Osaka, Japan

Website: https://www.sumitomo-pharma.com/

Pipeline: https://www.sumitomo-pharma.com/rd/clinical/pipeline.html

Partners: ERS Genomics


Sumitomo Pharma is a Japan-based company with global operations. The company is mainly involved in the gene-editing space through its license agreement with ERS Genomics, which it entered into in April 2022. The lead gene-editing programmes coming from the license agreement are yet to be disclosed.

See the full view ...